-
Important CHS survey on gene therapy
Companies will likely make submissions to Health Canada for approval of gene therapies for hemophilia A and B in the next 6-12 months. To best...
-
CHS Board of Directors
Meet the CHS Board of Directors! From left to right: First row: Cyril Boulila, Wendy Quinn, Leanne Owen. Back row: Dr. Lawrence Jardine, Derek Klatt,...
-
The CHS appoints new CEO
CLICK HERE to read the official announcement from CHS President, Wendy Quinn.
-
2021 CHS Annual Report
Please CLICK HERE to access the 2021 CHS Annual Report. Should you want to consult the complete Financial Statements, you can do so by clicking...
-
CHS reacts to Health Canada decision on relaxing donor selection criteria
April 28, 2022 (Montreal) – “The Canadian Hemophilia Society (CHS) is disappointed that Health Canada has not followed our advice regarding the changes to donor...